Vascular treatment method and apparatus

• US 5,900,433 A
• Filed: 12/23/1996
• Issued: 05/04/1999
• Est. Priority Date: 06/23/1995
• Status: Expired due to Term

• Current Assignee: Cormedics Corp.
• Original Assignee: Cormedics Corp.
• Inventors: Meador, James W., Igo, Stephen R.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US08/765,711
• Time in Patent Office: 862 Days
• Field of Search: 604/52, 604/51, 604/53, 604/23, 604/21, 604/26, 604/20, 604/19, 604/890, 604/891.1, 128/898, 514/530, 514/573
• US Class Current: 514/530
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008

Abstract

This invention relates to the method of use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically effective dosage.

Claims

1. A method of use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically effective dosage.

2. The method of use of claim 1 in which said congener is prostacyclin, prostaglandin E₁, a nitrovasodilator, or a combination thereof.

3. The method of use of claim 2 in which said nitrovasodilator is nitric oxide, a nitric oxide donor agent, or a combination thereof.

4. The method of use of claim 3 in which said nitric oxide donor agent is L-arginine, sodium nitroprusside, nitroglycerin, or a combination thereof.

5. The method of use of claim 1 in which said congener is sodium nitroprusside.

6. The method of use of claim 1 in which said treatment site is a coronary artery.

7. The method of use of claim 1 in which said treatment site is a vein graft for arterial bypass.

8. The method of use of claim 1 in which said step of administering includes delivering said congener in a controlled manner over a sustained period of time.

9. The method of use of claim 1 in which said step of administering comprises intrapericardially extravascularly delivering said congener to said coronary blood vessel.

10. The method of use of claim 9 in which said step of administering comprises intrapericardially infusing said congener through a percutaneously inserted catheter extravascularly to said coronary blood vessel.

11. The method of use of claim 1 in which said step of administering comprises transpericardially extravascularly delivering said congener to said coronary blood vessel.

12. The method of use of claim 11 in which said step of administering comprises transpericardially infusing said congener through a percutaneously inserted catheter extravascularly to said coronary blood vessel.

13. The method of use of claim 11 in which said step of administering comprises iontophoretically delivering said congener transpericardially extravascularly to said coronary blood vessel.

14. The method of use of claim 1 in which said step of administering comprises inserting extravascularly to said coronary blood vessel an implant capable of extended time release of said congener.

15. The method of use of claim 14 in which said step of inserting said extravascular implant comprises percutaneously inserting said implant proximately adjacent, onto, or into the pericardial sac surrounding the heart.

16. The method of use of claim 14 in which step of inserting said extravascular implant comprises surgically wrapping said implant around a vein graft used for an arterial bypass.

17. The method of use of claim 14 in which said extravascular implant is a biodegradable controlled-release polymer comprising said congener.

18. The method of use of claim 1 in which said dosage is effective to provide one or more of the therapeutic effects of promotion of vasodilation, inhibition of vessel spasm, inhibition of platelet aggregation, inhibition of vessel thrombosis, and inhibition of platelet growth factor release, at said treatment sites, without inducing systemic hypotension or anticoagulation.

19. The method of use of claim 1 in which said dosage is a rate from about 0.1 to about 3.0 μ

g/kg/min.

20. A method of use of a sodium nitroprusside composition of matter, which comprises percutaneously intrapericardially or transpericardially supplying sodium nitroprusside to a coronary blood vessel in a therapeutically effective dose.

21. A method of use of a congener of an endothelium-derived bioactive composition of matter which comprises percutaneously intrapericardially or transpericardially delivering said congener to a coronary blood vessel at a therapeutically effective dosage.